<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125055</url>
  </required_header>
  <id_info>
    <org_study_id>Illuminate-2</org_study_id>
    <nct_id>NCT05125055</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC</brief_title>
  <official_title>Neoadjuvant Toripalimab and Albumin Paclitaxel /Cisplatin Versus Docetaxel/ Cisplatin/ 5-fluorouracil (TPF) on Pathological Response in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel&#xD;
      /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally&#xD;
      advanced resectable oral squamous cell carcinoma (OSCC), and to determine the safety of&#xD;
      neoadjuvant TTP. In order to explore a better protocol of neoadjuvant therapy to improve the&#xD;
      efficacy in patients with locally advanced OSCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the previous &quot;Illuminate&quot; trial, neoadjuvant anti-programmed death-1 (PD-1) of Toripalimab&#xD;
      and Albumin paclitaxel /Cisplatin (TTP) therapy was used in 20 patients with locally advanced&#xD;
      and resectable oral squamous cell carcinoma (OSCC), and the neoadjuvant therapy was&#xD;
      well-tolerated. The major pathologic response (MPR) rate was 60% (12/20), including 30%&#xD;
      (6/20) pathological complete response (pCR). Furthermore, the MPR might transfer to survival&#xD;
      benefit in the patients received neoadjuvant therapy. Therefore, in this randomized trial, we&#xD;
      aimed to compare the pathological response of neoadjuvant TTP therapy versus TPF chemotherapy&#xD;
      in the patients with locally advanced OSCC (Illuminate-2 trial). A total of 80 patients will&#xD;
      be enrolled in this trial, and the primary endpoint is MPR rate. The neoadjuvant TTP arm will&#xD;
      receive two cycles of intravenous Albumin paclitaxel (260mg/ m^2), Cisplatin (75mg/ m^2) and&#xD;
      Toripalimab (anti-PD1 inhibitor, 240 mg) on d1 and d22, followed by the standard treatment of&#xD;
      surgery and postoperative adjuvant therapy. The neoadjuvant TPF arm will received two cycles&#xD;
      of intravenous Docetaxel (75mg/m^2), Cisplatin (75mg/m^2) on d1 (d22), and&#xD;
      5-Fu(750mg/m^2/day) for 5 days (d1-5 and d22-26), followed by the standard treatment of&#xD;
      surgery and postoperative adjuvant therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathologic response</measure>
    <time_frame>3 months</time_frame>
    <description>The major pathologic response (MPR): the percentage of tumor cells before and after treatment was compared according to biopsy specimens before neoadjuvant therapy and pathological specimens after surgery; the percentage of residual viable tumor (RVT) cells was evaluated on resected tumor slides. MPR was defined as ≤ 10% RVT%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year disease-free survival rate</measure>
    <time_frame>24 months</time_frame>
    <description>Disease-free survival was calculated from the date of randomization to tumor recurrence or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival rate</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival was calculated from the date of randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Oral Squamous Cell Carcinoma</condition>
  <condition>Neoadjvant Therapy</condition>
  <condition>Anti-PD-1</condition>
  <condition>Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant TTP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive two cycles of intravenous Albumin paclitaxel (260mg/ m^2), Cisplatin (75mg/ m^2) and Toripalimab (anti-PD-1 inhibitor, 240 mg) on d1 and d22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant TPF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will receive two cycles of intravenous Docetaxel (75 mg/m^2) on d1 and d22, Cisplatin (75 mg/m^2) on d1 and d22, and 5-Fluorouracil (750 mg/m^2/day) for 5 days (d1-5 and d22-26), the interval is 16±1 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab (anti-programmed death-1 inhibitor)</intervention_name>
    <description>The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.</description>
    <arm_group_label>Neoadjuvant TTP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin paclitaxel</intervention_name>
    <description>The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.</description>
    <arm_group_label>Neoadjuvant TTP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m^2 of Cisplatin will be used intravenously on the first day of each cycle.</description>
    <arm_group_label>Neoadjuvant TPF</arm_group_label>
    <arm_group_label>Neoadjuvant TTP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m^2 of Docetaxel will be used intravenously on the first day of each cycle.</description>
    <arm_group_label>Neoadjuvant TPF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.</description>
    <arm_group_label>Neoadjuvant TPF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-75 years old&#xD;
&#xD;
          2. Gender: male and female&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-2&#xD;
&#xD;
          4. Histopathological diagnosis of oral squamous cell carcinoma (including tongue, gums,&#xD;
             cheek, floor of mouth, hard palate, and posterior molar region)&#xD;
&#xD;
          5. Primary tumor with a clinical stage of III/IVA (T1-2/N1-2/M0 or T3-4a/cN0-2/M0,&#xD;
             AJCC2018)&#xD;
&#xD;
          6. Patients must have at least one measurable lesion according to the Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST v1.1)&#xD;
&#xD;
          7. Blood routine: white blood cells (WBCs) &gt;3,000/mm3, hemoglobin &gt;8 g/L, platelets&#xD;
             &gt;80,000/mm3&#xD;
&#xD;
          8. Liver function: alanine amino transferase/aspartate amino transferase (ALAT/ASAT) &lt;2.5&#xD;
             times the upper limit of normal and bilirubin &lt;1.5 times the upper limit of normal&#xD;
&#xD;
          9. Renal function: Serum creatinine &lt;1.5 times the upper limit of normal&#xD;
&#xD;
         10. Coagulation function: INR, PT, APTT&lt;1.5 times the upper limit of normal&#xD;
&#xD;
         11. Signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unresolved grade 2 [(Common Terminology Criteria for Adverse Events (CTCAE 5.0)] or&#xD;
             higher toxic reactions caused by previous anticancer treatments&#xD;
&#xD;
          2. Known allergic reaction to any ingredients or excipients of the therapy&#xD;
&#xD;
          3. Known history of malignancy, unless been cured and no recurrence for 5 years&#xD;
&#xD;
          4. Known history of radiation to head and neck&#xD;
&#xD;
          5. Active severe clinical infection (&gt; National Cancer Institute (NCI)-CTCAE version 5.0&#xD;
             grade 2 infection)&#xD;
&#xD;
          6. Obvious cardiovascular abnormalities [such as myocardial infarction, superior vena&#xD;
             cava syndrome, grade 2 or higher heart disease diagnosed according to the New York&#xD;
             Heart Association (NYHA) classification 3 months before enrollment]&#xD;
&#xD;
          7. Patients receiving immunology-based treatment for any reason&#xD;
&#xD;
          8. Patients with a history of active bleeding, coagulopathy, or receiving coumarin&#xD;
             anticoagulation therapy&#xD;
&#xD;
          9. Pregnant or lactating women&#xD;
&#xD;
         10. Uncontrollable hypertension (systolic blood pressure &gt;150 mmHg and/or diastolic blood&#xD;
             pressure &gt;90 mmHg) or cardiovascular diseases with clinical significance (such as&#xD;
             activity), such as cerebrovascular accidents (≤ 6 months before screening), myocardial&#xD;
             infarction (≤6 months before screening), unstable angina pectoris, NYHA grade II or&#xD;
             above congestive heart failure, or severe arrhythmia that cannot be controlled by&#xD;
             drugs or has a potential impact on trial treatment&#xD;
&#xD;
         11. Complicated with severe, uncontrolled infection or known human immunodeficiency virus&#xD;
             (HIV) infection, or diagnosed as acquired immunodeficiency syndrome (AIDS); or&#xD;
             uncontrolled autoimmune disease; or history of allogeneic tissue/organ&#xD;
             transplantation, stem cell or bone marrow transplantation, or solid organ&#xD;
             transplantation&#xD;
&#xD;
         12. Participation in other clinical trials within 30 days before enrollment&#xD;
&#xD;
         13. Other situations that the investigator considers unsuitable with respect to&#xD;
             participating in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lai-ping Zhong, MD, PhD</last_name>
    <phone>+862123271699</phone>
    <phone_ext>5160</phone_ext>
    <email>zhonglp@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lai-ping Zhong, MD, PhD</last_name>
      <phone>+86-21-23271699</phone>
      <phone_ext>5160</phone_ext>
      <email>zhonglaiping@163.com</email>
    </contact>
    <investigator>
      <last_name>Lai-ping Zhong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Lai-ping Zhong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol and the primary study report might be shared depending on the condition of trial completion.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

